Two executives at Teva (TEVA) sold company shares worth a combined total of about $3.02 million, according to filings submitted to the U.S. Securities and Exchange Commission (SEC).
According to the filings, Dov Bergwerk, who serves as an officer and the company’s interim chief legal officer, sold 26,260 ordinary shares at a price of $41.72 per share. The total proceeds from the sale amounted to about $1.1 million. Following the transaction, he directly owned 11,943 Teva shares.
At the same time, Mark Sabag, senior vice president for commercial operations in international markets, sold 46,000 shares at a weighted average price of about $41.93 per share. The transaction was worth about $1.93 million. Following the sale, he directly owned 80,760 company shares.
In total, the two executives sold 72,260 shares for about $3.02 million. Both transactions were reported using Form 4, which is used to report changes in the holdings of officers and interested parties in companies traded in the U.S.
It is important to note that share sales by executives do not necessarily indicate their assessment of the company’s future or an expectation that the stock will decline, and the transactions should also be examined in light of the sellers’ personal and financial circumstances.











